Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2024 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• Prescrire events
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

Check before deciding  Editorial  Many people take medicines regularly for months or even years. If their condition worsens or a new health problem develops, other medicines are often added. When prescribing, advising, dispensing or administering an additional drug, it is essential to consider the adverse effects that could result from interactions with the patient's current medications.   Full article available for download (free) 1 May 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Tezepelumab (Tezspire°) in severe asthma in adults and adolescents  Marketing Authorisations   Tezepelumab is a monoclonal antibody that binds to the cytokine thymic stromal lymphopoietin. It has been authorised in the European Union for use in adults and adolescents with severe asthma, as an add-on to insufficiently effective maintenance treatment with a high-dose inhaled corticosteroid combined with at least one other drug. In this situation, is tezepelumab more effective than an oral corticosteroid or any of the other monoclonal antibodies authorised in asthma, does it help reduce patients’ oral corticosteroid requirements, and what are its adverse effects? Full article available for download by subscribers (4 pages) 1 May 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The Prescrire Drug Awards for 2023 None of the drugs examined by Prescrire in 2023 represented a major therapeutic advance worthy of a Pilule d'Or (Golden Pill Award). Only one drug received an award, earning a place on the Honours List. Full article available for download (free) 1 May 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Pregabalin during the first trimester of pregnancy: probably a slight increase in major malformations  Adverse Effects   New pharmacoepidemiological data show a higher incidence of various major congenital malformations following in­-utero exposure to pregabalin than in control groups. What is the evidence for this risk, and what are the consequences in practice? Full article available for download by subscribers (2 pages) 1 May 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Efgartigimod alfa (Vyvgart°) in generalised myasthenia gravis  Marketing Authorisations   Efgartigimod alfa, an antibody Fc fragment that is claimed to increase IgG degradation by blocking the neonatal Fc receptor, has been authorised in the European Union as an add-on treatment in adults with generalised myasthenia gravis who have autoantibodies directed against acetylcholine receptors. Is efgartigimod alfa more effective at alleviating the symptoms of the disease than the other treatments proposed in this situation, does it prevent the complications of the disease, including myasthenic crisis, and what are its adverse effects? Full article available for download by subscribers (3 pages) 1 May 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ European Commission public consultation on the revision of European pharmaceutical legislation: Prescrire's response  Advancing Healthcare Policy   The European Commission has launched a major revision of European pharmaceutical legislation. In November 2023, it opened its proposals to public consultation, to which Prescrire has responded. While Prescrire welcomes several of the proposals, some of them need to be further developed. Others are counterproductive or even dangerous, and should be rejected. Full article (4 pages) available for download (free) 1 May 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Bad in food but fine in health products?  Outlook   Bisphenol A and titanium dioxide: the European Medicines Agency (EMA) disputes the need to remove these substances from health products, yet it is acknowledged that their presence in food is harmful. Full article available for download (free) 1 May 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON• Faricimab in age-related macular degeneration  • Semaglutide in secondary cardiovascular prevention • Paternal exposure to valproate drugs • Recurring criticisms of Prescrire: how do we answer?  > Subscribe now 1 May 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view. 1 November 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "Top Texts of 2023", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this sampling of texts from Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Inside, top articles from sections dedicated to new drugs authorised in Europe and key information on adverse drug effects, plus our annual update of drugs to avoid. > Click here for your free copy 1 August 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2024 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---